## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Lin, et al.

Serial No.:

To Be Assigned

Filed:

Concurrently Herewith

For:

Glial Cell Line-Derived Neurotrophic Factor

Docket No.:

S-225N

## ATTORNEY'S STATEMENT PURSUANT TO 37 CFR § 1.821(e)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The computer readable form in this application, Serial No. not yet assigned, is identical with that filed in Application Serial No. 08/182,183, filed May 23, 1994. In accordance with 37 CFR §1.821(e), please use the last-filed computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in the originally-filed specification of the instant application, or included herewith, whichever is applicable.

In addition, I hereby state that the paper copy of the Sequence Listing in this application and the computer readable form of the Sequence Listing submitted in the parent case are the same and contains no new matter.

Please send all future correspondence to:

US Patent Operations/RLS Dept. 4300, M/S 27-4-A AMGEN INC.

One Amgen Center Drive

Thousand Oaks, California 91320-1799

Respectfully submitted,

Robert L. Sharp

Attorney/Agent for Applicant(s)

Registration No.: 45,609 Phone: (805) 447-5992 Date: January 14, 2004

## **EXPRESS MAIL CERTIFICATE**

"Express Mail" mail labeling number:

EL360692085US

Date of Deposit:

January 14, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450...